AbbVie and Pfizer are compared as dividend-paying pharmaceutical giants facing patent cliffs. AbbVie shows stronger growth with $61.2B revenue (up 8.6%) and successful new product launches offsetting Humira losses, while Pfizer generated $62.6B revenue (down 1.6%) with higher dividend yield but concerns about future growth. The author recommends AbbVie for conservative investors due to its more stable business performance and predictable growth trajectory, despite Pfizer's attractive valuation metrics.

The Vanguard Health Care ETF (VHT) offers broader healthcare sector exposure with lower costs (0.09% expense ratio) and higher dividend yield (1.69%), while the SPDR S&P Biotech ETF (XBI) provides targeted biotech exposure with higher volatility but stronger recent 1-year returns (62.20% vs 13.00%). VHT is better suited for income-seeking investors seeking diversified healthcare exposure, while XBI appeals to aggressive investors seeking biotech-specific growth.

IHE (U.S. Pharmaceuticals ETF) significantly outperformed IXJ (Global Healthcare ETF) over the past year, driven largely by GLP-1 drug success, particularly from Eli Lilly. While IHE's concentrated focus on domestic pharma delivered 39.70% returns, IXJ's broader global healthcare approach provided more diversification but only 10% returns. Both funds charge similar fees, making the choice dependent on investor preference for concentration versus diversification.

The obesity drug market is projected to reach nearly $100 billion by decade's end. While Eli Lilly and Novo Nordisk dominate, two other companies—Viking Therapeutics and AbbVie—are positioned for significant growth. Viking is advancing VK-2735, a dual GLP-1/GIP receptor agonist in phase 3 trials with promising results. AbbVie is developing ABBV-295, a long-acting amylin analog with positive phase 1 data. Both stocks are predicted to potentially double in 2026 based on upcoming trial results and market expansion.

As investors shift from tech stocks to lower-risk investments, three dividend growth stocks are recommended: AbbVie, a Dividend King pharma company with a 3.2% yield and strong new drug pipeline; Procter & Gamble, a consumer staples Dividend King with a 3% yield trading below historical valuations; and Enterprise Products Partners, an energy infrastructure MLP with a 5.5% yield and 27 consecutive years of distribution increases.

Ichnos Glenmark Innovation (IGI) announced ISB 2301, a first-in-class multispecific antibody that targets three tumor-associated antigens and activates both T cells and NK cells for solid tumor treatment. The candidate, developed using IGI's proprietary BEAT® platform, demonstrated favorable safety profiles in preclinical studies and is expected to advance toward clinical trials with an IND submission planned by end of 2026.

Over 50 pharmaceutical companies are advancing 55+ pipeline drugs for pulmonary arterial hypertension (PAH) treatment. Recent developments include United Therapeutics' ralinepag meeting Phase III endpoints with 55% risk reduction, Gossamer Bio's seralutinib Phase III results, GSK's acquisition of 35Pharma for HS235, and Inhibikase Therapeutics enrolling patients in Phase III IMPROVE-PAH trial. Multiple novel mechanisms of action are being explored to address persistent clinical gaps in PAH management.

AbbVie and CVS Health appear expensive based on trailing P/E multiples (100+ and 42 respectively) due to non-recurring charges that depressed recent earnings. However, their forward P/E multiples (15 and 13) reveal they are actually attractive buys. Both companies offer solid dividend yields and strong fundamentals, making them undervalued when accounting for normalized earnings.

The article highlights two healthcare stocks with high dividend yields that are expected to raise payouts: AbbVie, a pharmaceutical company with 12 blockbuster drugs and Dividend King status, and Medtronic, the largest medical device company with 48 consecutive dividend raises and strong free cash flow generation.

Oruka Therapeutics reported strong phase 2a trial results for ORKA-001, showing 63.5% PASI 100 response rates compared to Skyrizi's typical 51%, potentially threatening AbbVie's $17.6 billion psoriasis drug. However, the article argues AbbVie remains a solid long-term investment due to its diverse pipeline, other growth drivers like Qulipta and Botox, and its status as a Dividend King.

The presbyopia market is projected to grow at a CAGR of 4.9% from 2026-2036, driven by an aging global population and expanding treatment options. The market was valued at USD 11 billion in 2025 across seven major markets, with the US accounting for 50% of the market. Multiple emerging therapies and devices are expected to enter the market, including Phentolamine, MicroLine, GLK-302, and CorVision, alongside already-approved treatments like VUITY, QLOSI, VIZZ, and YUVEZZI.

Chicago-based Cura Wealth Advisors sold 155,210 shares of Blackstone Mortgage Trust (BXMT) worth approximately $2.99 million in Q1 2026, reducing its position from 1.4% to 0.28% of assets under management. The sale comes as BXMT faces headwinds from office property concerns, despite the company maintaining a 98% performing loan portfolio and an attractive 9.4% dividend yield. The stock has significantly underperformed the S&P 500, which is up 30% while BXMT remains flat over the past year.